Literature DB >> 24186004

Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.

U Platzbecker1, H K Al-Ali2, N Gattermann3, D Haase4, V Janzen5, J Krauter6, K Götze7, R Schlenk8, F Nolte9, A Letsch10, O G Ottmann11, A Kündgen3, M Lübbert12, U Germing3, M Wermke1, H Reinhard13, C Weiss13, K Lieder13, G Ehninger1, O Leismann13, A Giagounidis14.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24186004     DOI： 10.1038/leu.2013.325

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.

Authors:  Andrea Kuendgen; Sabine Knipp; Frank Fox; Corinna Strupp; Barbara Hildebrandt; Christian Steidl; Ulrich Germing; Rainer Haas; Norbert Gattermann
Journal:  Ann Hematol       Date:  2005-12       Impact factor: 3.673

2.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

Review 3.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

4.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

5.  Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Authors:  Anas Younes; Anna Sureda; Dina Ben-Yehuda; Pier Luigi Zinzani; Tee-Chuan Ong; H Miles Prince; Simon J Harrison; Mark Kirschbaum; Patrick Johnston; Jennifer Gallagher; Christophe Le Corre; Angela Shen; Andreas Engert
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

6.  Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

Authors:  D J DeAngelo; A Spencer; K N Bhalla; H M Prince; T Fischer; T Kindler; F J Giles; J W Scott; K Parker; A Liu; M Woo; P Atadja; K K Mishra; O G Ottmann
Journal:  Leukemia       Date:  2013-02-06       Impact factor: 11.528

7.  A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.

Authors:  Eva Hellström-Lindberg; Nina Gulbrandsen; Greger Lindberg; Tomas Ahlgren; Inger Marie S Dahl; Ingunn Dybedal; Gunnar Grimfors; Eva Hesse-Sundin; Martin Hjorth; Lena Kanter-Lewensohn; Olle Linder; Michaela Luthman; Eva Löfvenberg; Gunnar Oberg; Anja Porwit-MacDonald; Anders Rådlund; Jan Samuelsson; Jon Magnus Tangen; Ingemar Winquist; Finn Wisloff
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

Review 8.  Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.

Authors:  H Miles Prince; Mark J Bishton; Ricky W Johnstone
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

9.  Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2007-06-27       Impact factor: 22.113

10.  Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

Authors:  Maria Teresa Voso; Valeria Santini; Carlo Finelli; Pellegrino Musto; Enrico Pogliani; Emanuele Angelucci; Giuseppe Fioritoni; Giuliana Alimena; Luca Maurillo; Agostino Cortelezzi; Francesco Buccisano; Marco Gobbi; Lorenza Borin; Anna Di Tucci; Gina Zini; Maria Concetta Petti; Giovanni Martinelli; Emiliano Fabiani; Paola Fazi; Marco Vignetti; Alfonso Piciocchi; Vincenzo Liso; Sergio Amadori; Giuseppe Leone
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531
View more
  8 in total

Review 1.  Panobinostat: first global approval.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

Review 2.  Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?

Authors:  Katja Sockel; Uwe Platzbecker
Journal:  Drugs       Date:  2018-12       Impact factor: 9.546

3.  Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.

Authors:  Yukio Kobayashi; Wataru Munakata; Michinori Ogura; Toshiki Uchida; Masafumi Taniwaki; Tsutomu Kobayashi; Fumika Shimada; Masataka Yonemura; Fumiko Matsuoka; Takeshi Tajima; Kimikazu Yakushijin; Hironobu Minami
Journal:  Int J Hematol       Date:  2017-09-13       Impact factor: 2.490

Review 4.  Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.

Authors:  Natalie Uy; Abhay Singh; Steven D Gore; Thomas Prebet
Journal:  Expert Opin Pharmacother       Date:  2017-08-01       Impact factor: 3.889

Review 5.  Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.

Authors:  Madhusoodanan Mottamal; Shilong Zheng; Tien L Huang; Guangdi Wang
Journal:  Molecules       Date:  2015-03-02       Impact factor: 4.411

6.  GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.

Authors:  Lacramioara Botezatu; Lars C Michel; Hideki Makishima; Thomas Schroeder; Ulrich Germing; Rainer Haas; Bert van der Reijden; Anne E Marneth; Saskia M Bergevoet; Joop H Jansen; Bartlomiej Przychodzen; Marcin Wlodarski; Charlotte Niemeyer; Uwe Platzbecker; Gerhard Ehninger; Ashwin Unnikrishnan; Dominik Beck; John Pimanda; Eva Hellström-Lindberg; Luca Malcovati; Jacqueline Boultwood; Andrea Pellagatti; Elli Papaemmanuil; Philipp Le Coutre; Jaspal Kaeda; Bertram Opalka; Tarik Möröy; Ulrich Dührsen; Jaroslaw Maciejewski; Cyrus Khandanpour
Journal:  Exp Hematol       Date:  2016-04-11       Impact factor: 3.084

Review 7.  Targeting EZH2 for cancer therapy: progress and perspective.

Authors:  Chi Han Li; Yangchao Chen
Journal:  Curr Protein Pept Sci       Date:  2015       Impact factor: 3.272

8.  The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.

Authors:  Joanna Zabkiewicz; Marie Gilmour; Robert Hills; Pares Vyas; Elizabeth Bone; Alan Davidson; Alan Burnett; Steven Knapper
Journal:  Oncotarget       Date:  2016-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.